Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
October 15th, 2014

Proactive Monitoring

By Margaret Shepard, Communications Associate

Edward Loftus Jr., M. D., discusses a recently published article in Inflammatory Bowel Diseases that looks at proactive Infliximab drug monitoring in patients. Infliximab treats Crohn's diseases and more recently, ulcerative colitis.

The recently published paper looks at proactive monitoring, instead of reactive monitoring which physicians have been doing. A physician at Bethel Decan Medical Center in Boston looked at 48 patients starting in 2009. The patients' blood levels were proactively checked regardless of the patients' condition. A control group of 78 patients either had a reactive approach or no drug monitoring at all.

A vast majority of patients did receive some adjustment in therapy. This resulted in patients staying on Infliximab for a longer period of time. 10% of the patients in the proactive arm resulted in less discontinuing Infliximab.

Read the full article online here.

For more information about IBD, visit mayoclinic.org/ibd.

Dr. Loftus is a gastroenterologist at Mayo Clinic.

Tags: Clinical Trials, Edward Loftus, IBD, monitoring

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy